^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

GB263T

i
Other names: GB263T, GB263tri
Company:
Walvax
Drug class:
EGFR inhibitor, c-MET inhibitor
Related drugs:
over2years
Characterization of GB263T, a tri-specific antibody against EGFR/cMET/cMET for NSCLC (AACR 2022)
Amivantamab, a bispecific antibody to EGFR/c-Met has shown that concurrent inhibition of EGFR and c-Met can overcome resistance of EGFR-TKIs and improve patient outcomes. GB263T is a novel tri-specific antibody that exhibited robust anti-tumor activity. The preclinical data indicate that GB263T has great potential to become an effective therapeutics in the treatment of NSCLC.
Late-breaking abstract
|
EGFR (Epidermal growth factor receptor) • FCGR3A (Fc Fragment Of IgG Receptor IIIa)
|
EGFR mutation • MET amplification • EGFR exon 20 insertion • MET exon 14 mutation • EGFR C797S • EGFR exon 20 mutation
|
Rybrevant (amivantamab-vmjw) • GB263T